Agios

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Agios and other ETFs, options, and stocks.

About AGIO

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. 

CEO
Brian M. Goff
CEOBrian M. Goff
Employees
488
Employees488
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2007
Founded2007
Employees
488
Employees488

AGIO Key Statistics

Market cap
2.48B
Market cap2.48B
Price-Earnings ratio
-6.12
Price-Earnings ratio-6.12
Dividend yield
Dividend yield
Average volume
608.42K
Average volume608.42K
High today
High today
Low today
Low today
Open price
$43.12
Open price$43.12
Volume
0.00
Volume0.00
52 Week high
$62.45
52 Week high$62.45
52 Week low
$23.42
52 Week low$23.42

Stock Snapshot

The current Agios(AGIO) stock price is $42.54, with a market capitalization of 2.48B. The stock trades at a price-to-earnings (P/E) ratio of -6.12.

On 2025-11-14, Agios(AGIO) shares started trading at $43.12, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 608.42K.

The stock's 52-week range extends from a low of $23.42 to a high of $62.45.

The stock's 52-week range extends from a low of $23.42 to a high of $62.45.

AGIO News

Simply Wall St 1d
Agios Pharmaceuticals: Assessing Valuation After New Mitapivat Data Announced for ASH 2025

Agios Pharmaceuticals (AGIO) revealed that new data on its lead candidate, mitapivat, will be shared at the upcoming ASH 2025 conference. The focus includes pro...

Agios Pharmaceuticals: Assessing Valuation After New Mitapivat Data Announced for ASH 2025
Simply Wall St 5d
Could Mitapivat Data Shift Agios Pharmaceuticals’ Competitive Edge in Rare Blood Disorders?

Agios Pharmaceuticals recently announced that new clinical and preclinical data on mitapivat, its oral pyruvate kinase activator, were featured in presentations...

Could Mitapivat Data Shift Agios Pharmaceuticals’ Competitive Edge in Rare Blood Disorders?

Analyst ratings

63%

of 8 ratings
Buy
62.5%
Hold
37.5%
Sell
0%

People also own

Based on the portfolios of people who own AGIO. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.